OBJECTIVES: This study sought to perform a systematic review with meta-analysis of randomized controlled trials comparing the use of ascorbic acid with placebo or other treatment options for the treatment of contrast induced-acute kidney injury (CI-AKI) in patients undergoing coronary angiography. BACKGROUND: CI-AKI remains the most widely discussed and debated topic in cardiovascular medicine, with its incidence increasing due to an increasing number of contrast media-enhanced radiological procedures being performed. METHODS: MEDLINE, Embase, and Cochrane central databases were searched from inception to May 2013, without language restrictions. For a study to be selected, it had to report the incidence of CI-AKI as an outcome measure. Studies were excluded if at least 1 study arm did not have ascorbic acid administered alone or with saline solution hydration. Data were extracted by 1 author, and random checks were made by another author. RESULTS: Nine randomized, controlled trials reported data on the incidence of CI-AKI in 1,536 patients who had completed the trial and were included in the final analysis. Patients receiving ascorbic acid had 33% less risk of CI-AKI compared with patients receiving placebo or an alternate pharmacological treatment (risk ratio by random-effects model: 0.672; 95% confidence interval, 0.466 to 0.969; p = 0.034). CONCLUSIONS: Ascorbic acid provides effective nephroprotection against CI-AKI and may form a part of effective prophylactic pharmacological regimens.
OBJECTIVES: This study sought to perform a systematic review with meta-analysis of randomized controlled trials comparing the use of ascorbic acid with placebo or other treatment options for the treatment of contrast induced-acute kidney injury (CI-AKI) in patients undergoing coronary angiography. BACKGROUND: CI-AKI remains the most widely discussed and debated topic in cardiovascular medicine, with its incidence increasing due to an increasing number of contrast media-enhanced radiological procedures being performed. METHODS: MEDLINE, Embase, and Cochrane central databases were searched from inception to May 2013, without language restrictions. For a study to be selected, it had to report the incidence of CI-AKI as an outcome measure. Studies were excluded if at least 1 study arm did not have ascorbic acid administered alone or with saline solution hydration. Data were extracted by 1 author, and random checks were made by another author. RESULTS: Nine randomized, controlled trials reported data on the incidence of CI-AKI in 1,536 patients who had completed the trial and were included in the final analysis. Patients receiving ascorbic acid had 33% less risk of CI-AKI compared with patients receiving placebo or an alternate pharmacological treatment (risk ratio by random-effects model: 0.672; 95% confidence interval, 0.466 to 0.969; p = 0.034). CONCLUSIONS:Ascorbic acid provides effective nephroprotection against CI-AKI and may form a part of effective prophylactic pharmacological regimens.
Authors: Shu Min Tao; Julian L Wichmann; U Joseph Schoepf; Stephen R Fuller; Guang Ming Lu; Long Jiang Zhang Journal: Eur Radiol Date: 2015-12-18 Impact factor: 5.315
Authors: José Mariani; Cristiano Guedes; Paulo Soares; Silvio Zalc; Carlos M Campos; Augusto C Lopes; André G Spadaro; Marco A Perin; Antonio Esteves Filho; Celso K Takimura; Expedito Ribeiro; Roberto Kalil-Filho; Elazer R Edelman; Patrick W Serruys; Pedro A Lemos Journal: JACC Cardiovasc Interv Date: 2014-10-15 Impact factor: 11.195
Authors: D Blair Macdonald; Casey D Hurrell; Andreu F Costa; Matthew D F McInnes; Martin O'Malley; Brendan J Barrett; Pierre Antoine Brown; Edward G Clark; Anastasia Hadjivassiliou; Iain Donald Craik Kirkpatrick; Jeremy Rempel; Paul Jeon; Swapnil Hiremath Journal: Can J Kidney Health Dis Date: 2022-05-24
Authors: Michele Andreucci; Teresa Faga; Antonio Pisani; Massimo Sabbatini; Ashour Michael Journal: Biomed Res Int Date: 2014-08-14 Impact factor: 3.411